EN CN

NEWS RELEASES

YEAR

ALL

2019

2018

2017

2016

2015

2014

CANBRIDGE PHARMACEUTICAL AND WUXI BIOLOGICS ENTER INTO STRATEGIC PARTNERSHIP FOR RARE DISEASE THERAPEUTICS OCT 23, 2018
CANBRIDGE LIFE SCIENCES RECEIVES APPROVAL TO COMMENCE CAN017 IB/III TRIAL IN ESOPHAGEAL SQUAMOUS CELL CANCER (ESCC) IN CHINA AUG 14, 2018
CANBRIDGE LIFE SCIENCES APPOINTS CHIEF MEDICAL OFFICER JUL 31, 2018
CANBRIDGE LIFE SCIENCES APPOINTS VICE PRESIDENT OF CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS AND DIRECTOR OF QUALITY ASSURANCE MAY 08, 2018
CANBRIDGE RECEIVES CHINA FOOD AND DRUG ADMINISTRATION APPROVAL FOR CAN002 AS CANCER ADJUVANT THERAPY APR 26, 2018
CANBRIDGE RECEIVES APPROVAL TO COMMENCE CAN008 PHASE II/III TRIAL IN GLIOBLASTOMA MULTIFORME (GBM) IN CHINA APR 12, 2018
INDUSTRY VETERAN JOINS CANBRIDGE LIFE SCIENCES ADVISORY TEAM FEB 13, 2018
PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA FEB 02, 2018
CANBRIDGE APPOINTS SUNNY ZHANG AS VICE PRESIDENT OF REGULATORY AFFAIRS AND QUALITY JAN 16, 2018

«
1
2
3
4
5
6
7
8
9
»

PARTNERSHIP &
RECOGNITION

WORKING AT CANBRIDGE

EMPLOYEES’ WORD

OPENING POSITIONS

TEL: 86-10-84148018

FAX: 86-10-84148017

Product Hotline: 86-400-821-5085

ADD: Suite 301，3F，Timeloit，No.17 RongChuang Road，Chaoyang District， Beijing，China

EMAIL: info@canbridgepharma.com

Adverse Events Reporting: PV@canbridgepharma.com

Copyright ©:CANbridge Life Sciences Ltd. ICP:12036158-1 Powered By Clouddream